[1] 魏振衡,张军堂.经皮冠状动脉介入治疗术前单次负荷剂量与常规剂量瑞舒伐他汀对冠心病患者预后的影响[J].临床荟萃,2018,33(6):494-497. [2] 鲜廉杰. 乌司他丁联合大剂量阿托伐他汀对冠心病合并糖尿病患者PCI术后肾功能的影响[J].黑龙江医学,2020,44(6):801-803. [3] Kyohei Marume,Seiji Takashio,Toshiyuki Nagai,,et al.Effect of Statins on Mortality in Heart Failure With Preserved Ejection Fraction Without Coronary Artery Disease-Report From the JASPER Study-[J].Circulation journal,2019,83(2):357-367. [4] 石金铮,秦少强,王蕊,等.瑞舒伐他汀联合还原型谷胱甘肽对老年冠心病患者PCI术后MACE发生率和血清Visfatin、Treg水平的影响[J].中国老年学杂志,2020,40(4):678-681. [5] 张启杰,鄢高亮,焦慧,等.瑞舒伐他汀辅以替格瑞洛对PCI老年冠心病患者心功能及血脂的影响[J].徐州医科大学学报,2020,40(4):250-254. [6] 桑小闯,郭长青.大剂量瑞舒伐他汀钙联合尼可地尔对老年冠心病合并糖尿病PCI术后患者疗效观察及对肾功能影响[J]. 淮海医药,2020,38(1):8-11. [7] LEE JIMIN,LEE SUKHYANG.Comparative Effectiveness of Combination Therapy with Statins and Angiotensin Converting Enzyme Inhibitors versus Angiotensin II II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population‐Based Cohort Study in Korea[J].Pharmacotherapy:The Journal of Human Pharmacology and Drug Therapy,2018,38(11):1095-1105. [8] 李原,卜伟.老年冠心病患者PCI术前应用单次大剂量瑞舒伐他汀对对比剂肾病的预防效果[J].河南医学研究,2020,29(32):5986-5988. [9] 黎素军. 对接受PCI的冠心病患者在术前应用不同剂量的阿托伐他汀钙对其预后的影响[J].当代医药论丛,2020,18(16):22-23. [10] Jean Ferrières,Maja Velkovski Rouyer,Dominik Lautsch,et al.Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study[J].Archives of cardiovascular diseases,2017,110(3):167-178. [11] 徐青,严卫国,曹立平,等.强化他汀对PCI术后老年冠心病患者血清炎症因子及心肌酶谱水平的影响[J].安徽医学,2019,40(6):686-689. [12] 雷肖蠢,邱军杰.不同负荷剂量阿托伐他汀钙对高龄冠心病患者经皮冠状动脉介入术后预后影响的对比研究[J].实用心脑肺血管病杂志,2017,25(3):58-61,72. |